|Day Low/High||120.09 / 123.91|
|52 Wk Low/High||78.26 / 219.75|
When stocks move with unusual volume, it can signal insider buying and selling.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
We expect the $30 level to act as resistance.
Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.
Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.
Here are the industries and stocks that have seen heavy insider buying in the past two weeks.
The damage to a big drug's approval odds is much less than is presently priced into LGND.